Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the drug market for multiple sclerosis (MS) will be driven by growth in the number of drug-treated patients. According to the new Pharmacor study entitled Multiple Sclerosis, in 2002, 64% of diagnosed relapsing-remitting MS (RR-MS) patients and 31% of diagnosed chronic progressive MS (CP-MS) patients received drug therapy. These numbers increase to 74% and 40% respectively, in 2012.

"The increase in the number of RR-MS patients that are drug treated will have a large impact on the market because this population represents 65% of all MS patients, but we also expect expanded treatment in the CP-MS population. This growth will be fueled by three major factors," said Kate Hohenberg, therapeutic area director for Cognos at Decision Resources. "First, drug-treatment rates will increase as physicians begin prescribing disease-modifying agents to patients in previously underserved subgroups, such as early-stage MS patients and CP-MS patients who are relapsing. Second, drug-treatment rates will be driven by a growing acceptance of disease- modifying therapies by neurologists and regulatory agencies. Third, the availability of new MS therapies will also contribute to growth in the number of patients who receive drug therapy."

About Multiple Sclerosis

MS is a debilitating, chronic disease and is the second-most common cause, after trauma, of neurological disability in young and middle-aged adults. The MS population is relatively small (approximately 600,000 prevalent cases in 2002), and Decision Resources estimates that 86% of prevalent cases are diagnosed but only 53% are treated with drug therapy to manage the disease. This small patient base restricts drug sales.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Multiple Sclerosis is a Cognos study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Sales of Immunosuppressants for the Treatment of Ulcerative Colitis Will Double by 2012

View Now